CoreCap Advisors’s ImmunityBio IBRX Stock Holding History

CoreCap Advisors’s Portfolio IBRX Stock Details IBRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$201	Hold	23	–	–	﹤0.01%	3006
2026 Q1	$176	Buy	+23	New	+$157	﹤0.01%	2773
2025 Q1	–	Sell	-70	Closed	-$179	–	3217
2024 Q4	$179	Buy	+70	New	+$292	﹤0.01%	2732

Other funds holding IBRX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

CoreCap Advisors's IBRX Position: Q2 2026 in Review

CoreCap Advisors held its ImmunityBio (IBRX) position steady in Q2 2026 at 23 shares worth $201. The position accounts for ﹤0.01% of the portfolio, ranked #3006.

CoreCap Advisors first reported a position in IBRX in Q4 2024 and has held it in 3 quarters since. 404 funds tracked by Wall St. Rank hold IBRX as of Q2 2026.

CoreCap Advisors held 23 shares of ImmunityBio worth $201 as of Q2 2026.
CoreCap Advisors left its ImmunityBio share count unchanged in Q2 2026.
ImmunityBio made up ﹤0.01% of CoreCap Advisors's portfolio in Q2 2026, its #3006 holding.
CoreCap Advisors first reported a position in ImmunityBio in Q4 2024 and has held it in 3 quarters since.
404 funds tracked by Wall St. Rank held ImmunityBio as of Q2 2026.

Based on CoreCap Advisors's 13F filing for Q2 2026, filed 6 Jul 2026.